ABOUT OPNA BIO

Opna Bio is a clinical stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics. The Opna team has a proven track record of scientific expertise and commercial value creation, having advanced multiple FDA-approved drugs to market.

Opna’s lead clinical compounds include OPN-2853, a bromodomain and extra-terminal motif (BET) inhibitor, being evaluated in patients with myelofibrosis in combination with ruxolitinib, and OPN-6602, an oral, small molecule inhibitor of the E1A binding protein (EP300) and CREB-binding protein (CBP), currently in a Phase 1 clinical trial in multiple myeloma patients.

Efficacy and Safety by Design

Opna Bio has rationally designed epigenetic modulators that overcome safety and tolerability issues associated with small molecule inhibitors of this class.

Both OPN-6602 and OPN-2853 have a unique pharmacokinetic profile that enables “pulsatile dosing.” The compounds were synthesized to have a short half life and high C-max, enabling daily dosing and prolonged pharmacodynamic response.

The company also has a research program aimed at disrupting the actions of an unprecedented new cancer target – fragile-X multifunctional RNA-binding protein (FMRP).

The role of FMRP in cancer was elucidated in the laboratory of Dr. Douglas Hanahan, co-founder of Opna Bio and co-author of the seminal “Hallmarks of Cancer” series, which proposed a set of traits commonly acquired by human cancer cells and crucial for the formation of malignant tumors.

View Pipeline